Top broker tips Ramsay Health Care (ASX:RHC) share price to rise 14%

Ramsay Health Care could be a healthcare share to buy…

| More on:
Five healthcare workers standing together and smiling.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Ramsay Health Care's shares are down almost 10% in 2022
  • Goldman Sachs sees this as a buying opportunity
  • This morning the broker reiterated its buy rating and $74.00 price target on the company's shares

The Ramsay Health Care Limited (ASX: RHC) share price was a positive performer on Thursday.

The private hospital operator's shares rose 0.6% to $65.15.

Though, despite this gain, the Ramsay Health Care share price remains down almost 10% in 2022.

Is the Ramsay Health Care share price in the buy zone?

While the weakness in the Ramsay Health Care share price in 2022 has been disappointing for shareholders, it could be a buying opportunity for others.

That's the view of the team at Goldman Sachs, which this morning reiterated its buy rating on the company's shares.

And with Goldman holding firm with its $74.00 price target, this suggests there's potential upside of almost 14% for the Ramsay Health Care share price from current levels.

What did the broker say?

This week Goldman hosted Ramsay Health Care's CEO Craig McNally and CFO Martyn Roberts for an operational update and broader strategic discussion.

Following the meeting, Goldman commented: "With restrictions continuing to ease across all major markets, RHC is seeing a stronger, albeit uneven, volume development through 2H22 to date. As in previous post-restriction periods, there is a short-term dilutive skew to case-mix, which RHC confidently expects to normalise through coming quarters. Whilst staffing availability/cost remains a primary challenge across all hospital operators, RHC appears more favourably positioned than most global peers."

The broker also spoke to Ramsay Health Care about acquisitions. Management appeared to indicate that the focus would be on smaller bolt-on acquisitions rather than anything material.

It explained: "Per management, any further M&A efforts in the near-term are likely to focus on bolt-ons for Elysium (i.e. mental health facilities in the UK), and smaller primary care centers/specialists in Scandinavia. We did not sense appetite for larger, strategic assets any time soon."

Overall, Goldman appears to have come away from the meeting feeling confident about its rating on the Ramsay Health Care share price and has reiterated its buy rating.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

A male ASX investor sits cross-legged with a laptop computer in his lap with a slightly crazed, happy, excited look on his face while next to him a graphic of a rocket shoots upwards with graphics of stars scattered around it
Healthcare Shares

Up 10x since July, could this hot ASX stock be the next Droneshield?

Investors chase asymmetric upside and 4DMedical is one of the ASX's hottest stocks right now.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Is Medibank stock a buy for its 5.5% dividend yield?

This business is providing investors with very healthy dividends.

Read more »

A doctor shrugs and holds his hands out.
Healthcare Shares

Down 36% in 2025, should you buy CSL shares today?

A leading investment expert offers his outlook for CSL’s beaten-down share price.

Read more »

Three guys in shirts and ties give the thumbs down.
Healthcare Shares

Why did Macquarie just downgrade CSL shares?

The broker has taken an axe to its valuation of this biotech giant.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which drug company could pile on almost 30% in gains according to RBC Capital?

This drug company has plenty of irons in the fire, RBC Capital Markets says.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

This ASX 200 stock is charging higher on FDA approval news

This stock is avoiding the market weakness on Monday. Let's find out why.

Read more »